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(Sanofi-Winthrop, Riells y Viabrea, Spain) for
30 days. Criteria for eligibility, randomisation
of patients and blinding were those used in our
previous randomised study.1 Following laparo-
scopic cholecystectomy, GB specimens were
collected for routine histology and immuno-
histochemisty, the latter performed by the
streptavidin–biotin method. Mouse monoclo-
nal antibodies against COX-2 protein (clone
CX-294; Dako, Glostrup, Denmark) and
mouse monoclonal antibodies against CD68
(clone M7103; Dako) were used. Part of the
GB tissue was collected for muscle cell con-
traction to cholecystokinin 8 (CCK-8) studies
as well as for measurement of prostaglandin
(PG) E2 levels as described elsewhere.1
Following randomisation, eight patients
received UDCA and 11 received placebo, for
30 days. Staining with haematoxylin &
eosin revealed chronic cholecystitis, with
mild inflammatory infiltrates, in all GBs
with gallstones, treated with UDCA or
placebo. No histopathological lesions were
observed in GBs from a control group,
represented by 10 alithiasic GBs removed
from patients with neoplastic diseases not
involving the GB. The number of CD68
positive macrophages in the muscle layer of
GBs from gallstone patients was signifi-
cantly higher compared to that in control
patients. In UDCA-treated patients, the
number of CD68 positive macrophages, in
GB muscle, was significantly lower when
compared to that in placebo-treated
patients. Positive COX-2 expression was
almost exclusively present in macrophages
within the muscle layer (fig 1). The number
of COX-2 positive cells was higher in
muscle from symptomatic gallstone
patients compared to controls and, likewise
macrophages, significantly lower following
UDCA treatment (table 1, fig 1). A direct
and significant correlation was observed
between positivity for CD68 and COX-2
(Spearman’s r= 0.7, p,0.01). As in our
previous study, the production of PGE2
was significantly lower, following UDCA
than after placebo. Furthermore, muscle
contraction, induced by increasing concen-
trations of CCK-8 (assessed in four patients
in each group) was significantly higher in
the UDCA, compared to placebo, group
(maximal contraction to CCK-8 1028 mol/l
was 25.1 (SD 3) vs 12 (SD 4)%, respec-
tively; p,0.001). Our more recent data
show that an inflammatory macrophage
infiltrate is present in the GB muscle layer
of cholesterol gallstone patients. UDCA
decreases the presence of macrophages in
the muscle layer and confirms improve-
ment in GB muscle cell contraction. These
results suggest that activated macrophages
play a role in muscle cell dysfunction and
add insight into the anti-inflammatory
action of UDCA, which may explain some
of the therapeutic effects of this bile acid in
liver diseases as well as other gastrointest-
inal inflammatory conditions.
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Pathological lesions in colonic
biopsies during Parkinson’s
disease
Parkinson’s disease (PD) is a neurodegenera-
tive condition that affects 1% of the
population over 65 years of age. The two
pathological hallmarks of PD are a loss of
dopaminergic neurons in the substantia
nigra (SN) and the presence of cytoplasmic
eosinophilic inclusions termed Lewy bodies
(LBs), whose main component is phosphory-
lated a-synuclein.1 This degeneration of SN
neurons leads to a dopamine deficiency
Figure 1 Immunohistochemistry for CD68 and cyclooxygenase-2 (COX-2) in muscularis
macrophages. CD68 positive cells, were quite evenly distributed in muscle layer of the gallbladder in
placebo-treated gallstones patients (A) and were scarcely present in gallbladder of ursodeoxycholic
acid (UDCA)-treated patients (B). A similar pattern was exhibited by COX-2 positive cells, in muscle
layer of gallbladder in placebo-treated patients (C) and UDCA-treated patients (D). A/C, B/D refer to
the same patient. The figure shows corresponding fields for each patient. Original magnification,
6200. High power field, 6400.
Table 1 Mean number (with SD in
parentheses) of positively stained cells in 10
consecutive microscopic fields
Controls Placebo UDCA
CD68 11.9 (8.1) 36.2 (11)* 19.6 (6)**
COX-2 10.5 (6.8) 30.6 (12)* 15.2 (5.5)**
*p,0.001 vs controls; **p,0.01 vs placebo.
COX-2, cyclooxygenase-2; UDCA, ursodeoxycholic acid.
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responsible for the major motor symptoms.
Nevertheless, it has become increasingly
evident that PD is a multicentric neurode-
generative process that also affects neuronal
structures outside the SN.2 In this context,
various reports performed on surgical or
autopsy specimens have shown that the
enteric nervous system (ENS) is affected
during PD.3 4 However, it is still a matter of
debate whether these alterations occur early
in the course of the disease. This is mainly due
to a lack of accessibility to the ENS in the
living patients. Therefore, demonstrating
(1) the ability to study the ENS using routine
colonic biopsies and (2) the presence of lesions
characteristics of PD could be relevant for an
early diagnosis of the disease and to better
understand its pathophysiology.
We therefore performed routine colonic
biopsies in five PD patients complaining of
functional constipation (63 (SD 7) years, three
men; all had disease duration .5 years). Five
healthy age-matched patients (61 (SD 6.5)
years, one man) requiring a total colono-
scopy for colorectal cancer screening were
included as controls. They had no known
neurological disease. None suffered from
functional digestive symptoms. In order to
avoid any specific role for chronic constipa-
tion, we included three additional non-age-
matched patients (52 (SD 5) years, no
men) who underwent total colonoscopy
for the assessment of a chronic intractable
constipation as additional controls. Written
consent was obtained according to the
principles of the Declaration of Helsinki.
Four biopsies were taken from the ascend-
ing colon during colonoscopy. Biopsies were
performed using standard biopsy forceps
without needles (FB210K; Olympus, Tokyo,
Japan). Samples were immediately immersed in
4uC saline solution and microdissected in order
to separate the submucosa (containing the
internal submucosal plexus) from the mucosa.
The submucosa were then fixed in 4% para-
formaldehyde. Imunohistochemical studies
were then performed on these tissues using a
combination of antibodies against rabbit anti-
tyrosine hydroxylase (TH) (1:500, Pel-Freez,
Rogers, Arkansas, USA), rabbit anti-dopamine-
b-hydroxylase (DBH) (1:250, Millipore, Saint-
Quentin-en-Yvelines, France), mouse anti-Hu
C/D (1:200, Invitrogen, Cergy-Pontoise,
Fance), rabbit anti-phosphorylated a-synuclein
(1:5000, WAKO, Osaka, Japan) or rabbit anti-
neurofilament 200 kDa (1:250; Millipore) as
previously described.5
In control patients, individual biopsies
contained 11.2 (SD 7.9) ganglia and each
ganglia contained 5.6 (SD 1.9) Hu-immu-
noreactive (IR) neurons. In PD patients, the
number of ganglia per biopsies was similar
to controls (13.6 (SD 5.3); p = 0.22). In
addition, the number of Hu-IR neurons per
ganglion in PD was unchanged as compared
to controls (7.0 (SD 1.6); p = 0.25) (fig
1A,C). Constipated controls did not differ
from PD patients in the number of ganglia
per biopsy (11.3 (SD 1.5); p = 0.57) or in the
number of neurons per ganglion (5.5 (SD 0.6);
p = 0.19) (fig 1C).
In healthy controls, 11.6 (SD 5.0)% of
Hu-IR neurons were TH-IR. In PD
patients, the proportion of TH-IR neurons
was unchanged as compared to controls
(12.3 (SD 3.3)%; p = 0.80) (fig 1D–F). In
constipated patients, the proportion of
TH-IR neurons was similar to the one of
PD patients (8. (SD 2.7)%; p = 0.12)
(fig 1F). In all groups no neuronal body
was DBH positive, suggesting that all TH-
IR neurons in the submucosal plexus were
dopaminergic. These results are consistent
with a previous report by Singaram et al6
showing the absence of loss of TH-IR
neurons in the submucosal and myenteric
plexuses of PD patients, suggesting that it
is not a marker of choice for detecting PD
lesions in the ENS.
However, immunohistochemical staining
with an antibody against phosphorylated
a-synuclein, revealed that 4 out of 5 PD
patients had phospho-a-synuclein-IR neur-
ites (identified with neurofilament (NF) in
the submucosa (fig 2A,F). These phospho-
a-synuclein-IR neurites were absent in both
control and constipated patients. In some
cases, large aggregates were observed in
dystrophic NF-IR neurites (fig 2E), a
pattern reminiscent of Lewy neurites.
Taken together, our pilot study showed
that routine colonic biopsies can be used to
study the submucosal plexus of the ENS. In
addition, we identified for the first time in
the gut of living PD patients lesions similar
to the ones observed in the brain. This
technique could be a reliable tool to detect
early lesions in the gut during the course of
PD in order to better understand the
pathogenesis of the disease and/or to iden-
tify novel biomarkers.
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Figure 1 Submucosal neuron counts and dopaminergic phenotype are unchanged in patients with
Parkinson’s disease (PD). Hu-immunoreactive (IR) submucosal neurons were identified in the colon
of controls (n = 5) (A), PD patients (n = 5) (B) and constipated patients (n = 3). There was no
change in the number of Hu-IR submucosal neurons per ganglion in the three conditions (C). Double
labelling with antibodies against Hu (A,B) and tyrosine hydroxylase (TH) (D,E) showed that
occasional submucosal neurons were TH-IR (arrow heads). No significant decrease in the
proportion of TH-IR submucosal neurons occurred in PD and in constipated patients (F). Each circle,
square and triangle represents one control, PD or constipated patient, respectively. Horizontal bars
represent the mean. Scale bar: 20 mm. CTL, control; CP, constipated patient.
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CORRECTION
doi:10.1136/gut.2007.119446corr1
R Spiller, Q Aziz, F Creed, et al. Guidelines
on the irritable bowel syndrome: mechan-
isms and practical management (Gut
2007;56:1770–98). In paragraph 4.4.1 the
sentence ‘‘This in turn acts on the adrenal
medulla, resulting in cortisol secretion into
the circulation’’ should read ‘‘This in turn
acts on the adrenal cortex, resulting in
cortisol secretion into the circulation’’.
Figure 2 Phospho-a-synuclein-positive submucosal neurites differentiate Parkinson’s disease
patients from controls. Double labelling with antibodies against neurofilament (NF) (A,B) and
phosphorylated a-synuclein (C,D) revealed that some NF-immunoreactive (IR) neuritic structures
were also phospho-a-synuclein-IR (merged image in E,F) in the majority of Parkinson’s disease
patients, but in none of the controls. Occasionally the inclusion-bearing neurites displayed
dystrophic alterations (A,C,E). Scale bar: 30 mm.
ANSWER
From the question on page 1673
The patient had a large inflammatory abdominal aortic
aneurysm. The abdominal CT scan shows a large infrarenal
aortic aneurysm with a maximum diameter of 7.5 cm extending
into the iliac vessels. There is an enhancing soft-tissue cuff
surrounding the anterolateral margin of the aneurysm. The
aneurysm appears to compress the third part of the duodenum
(fig 1 below), which, however, was not detected at endoscopy.
These CT findings were suggestive of an inflammatory
aneurysm. Inflammatory abdominal aortic aneurysms represent
3–10% of all abdominal aortic aneurysms and occur predomi-
nantly in men.1 They differ from atherosclerotic aneurysms in
that patients often present with abdominal symptoms or
anorexia, weight loss, and raised inflammatory markers. CT
has a specificity of 99.7% for diagnosis of inflammatory
aneurysms,2 usually showing periaortic fibrosis as a cuff of
enhancing soft tissue surrounding the anterolateral margin of
the aneurysm. If periaortic fibrosis is extensive, adjacent
abdominal structures may be compressed and adherent, most
commonly the third part of the duodenum.1 Although rare,
inflammatory abdominal aortic aneurysms should be kept in
mind as a cause of abdominal pain and/or anorexia, weight loss,
and raised inflammatory markers. The natural history of
inflammatory abdominal aortic aneurysms remains unknown,
with 3.3–14% patients presenting with acute or chronic rupture.1
As regards to management, the literature supports an operative
approach with a 30 day operative mortality rate of up to 9%.1
Complete regression of fibrosis and inflammatory process occurs
in up to one-half of patients at long-term follow-up post-
operatively. Clinical symptoms (such as weight loss and gastro-
intestinal symptoms) reverse in 93% of the patients after an
operation.3 Endovascular therapy is also a potential treatment
Editor’s quiz: GI snapshot
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